International Flavors & Fragrances Inc.'s Stock Analysis

International Flavors & Fragrances Reports Q1 2026 Financial Results

International Flavors & Fragrances (IFF) reported a decrease in net sales for the first quarter of 2026, totaling $2.74 billion, down 4% from the previous year. However, on a currency neutral basis, sales increased by 3%, with growth observed across all business segments. The company achieved a reported income before taxes of $209 million and an adjusted operating EBITDA of $568 million, reflecting an 8% increase on a comparable basis. Earnings per share for the quarter were reported at $0.66, with an adjusted EPS of $1.25 per diluted share. Cash flow from operations saw a significant increase of $130 million year-over-year, totaling $257 million, while free cash flow reached $92 million, up $144 million from the prior year.

The company is maintaining its full-year 2026 financial guidance, expecting sales in the range of $10.5 billion to $10.8 billion and adjusted operating EBITDA between $2.05 billion to $2.15 billion. IFF noted that divestitures would adversely impact both sales and adjusted operating EBITDA growth by approximately 5% in 2026. The company is also in the process of selling its Food Ingredients business, aiming to maximize shareholder value, while continuing to focus on productivity and innovation in a challenging operating environment.

May 05, 2026 16:17:59

International Flavors & Fragrances Annual Meeting Results Summary

On April 29, 2026, International Flavors & Fragrances Inc. held its Annual Meeting of Shareholders where ten individuals were elected to the Board of Directors for terms expiring in 2027. The meeting also included the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026 and an advisory vote on the compensation of named executive officers, which was approved.

The final voting results for each proposal were detailed in the Company’s Proxy Statement filed on March 18, 2026. The outcomes included the number of votes cast for, against, abstentions, and broker non-votes regarding the elected directors and the ratification of the accounting firm, as well as the advisory compensation vote.

May 04, 2026 17:06:58

International Flavors & Fragrances Reports 2025 Financial Results

International Flavors & Fragrances Inc. reported financial results for the fourth quarter and full year ended December 31, 2025. The company achieved net sales of $10.89 billion for the full year, a decrease of 5% compared to the previous year. On a currency neutral basis, adjusted operating EBITDA increased by 7%, reaching $2.086 billion. The company also recorded a loss before taxes of $412 million and an adjusted EPS of $4.20 per diluted share. In the fourth quarter, reported net sales were $2.59 billion, down 7% year-over-year, while adjusted EPS was $0.80 per diluted share.

In 2025, IFF initiated a sale process for its Food Ingredients segment and focused on optimizing its portfolio through divestitures. The company reported varied performance across its segments, with the Taste segment showing a 4% increase in currency neutral sales, while the Food Ingredients segment experienced a 3% decline. Looking ahead, IFF expects full year 2026 sales to range from $10.5 billion to $10.8 billion, with adjusted operating EBITDA projected between $2.05 billion and $2.15 billion. The company anticipates a 1% to 4% growth in currency neutral sales for 2026.

Feb 11, 2026 16:24:36

International Flavors & Fragrances Amends Bylaws Effective Immediately

On October 29, 2025, the Board of Directors of International Flavors & Fragrances Inc. approved amended and restated bylaws, which are now effective immediately. The summary provided does not include all details of the amendments, and investors are encouraged to refer to the complete text of the Bylaws attached as Exhibit 3.1 for more information.

The report also notes that it has been signed on behalf of the company in accordance with the Securities Exchange Act of 1934. This amendment to the bylaws may have implications for corporate governance and operational procedures within the company.

Nov 04, 2025 16:06:42

International Flavors & Fragrances Reports Q3 2025 Financial Results

International Flavors & Fragrances (IFF) reported net sales of $2.69 billion for the third quarter of 2025, marking an 8% decrease compared to the same period last year. However, on a currency-neutral basis, sales remained flat, supported by growth in the Scent and Taste segments. Adjusted operating EBITDA for the quarter was $519 million, reflecting a 7% improvement on a comparable basis, primarily due to productivity gains and favorable net pricing. The company reported earnings per share of $0.16 and adjusted EPS of $1.05 per diluted share.

Despite the challenges in the operating environment, IFF reiterated its full-year 2025 financial guidance, expecting sales between $10.6 billion and $10.9 billion, and adjusted operating EBITDA between $2 billion and $2.15 billion. The company anticipates a 1% to 4% growth in comparable currency-neutral sales and a 5% to 10% increase in adjusted operating EBITDA for the year. Additionally, IFF noted that recent foreign exchange rates could negatively impact sales and EBITDA growth by approximately 1% and 3%, respectively, and that the divestiture of Pharma Solutions would also affect overall financial performance for the year.

Nov 04, 2025 16:21:11

Board Changes at International Flavors & Fragrances Announced

International Flavors & Fragrances has announced changes to its Board of Directors, effective October 20, 2025. Mr. Brett Icahn has replaced Mr. Vincent Intrieri as the Icahn Designee director, while Dr. Richard Mulligan has taken the place of Ms. Margarita Paláu-Hernández. Both departing directors stated that their exits were not due to disagreements with the company or its management. The appointments of Mr. Icahn and Dr. Mulligan align with the terms of a Cooperation Agreement with the Icahn Group.

Mr. Icahn, an investor and portfolio manager at Icahn Capital, has extensive experience serving on various boards, while Dr. Mulligan is a distinguished academic and has held significant positions in biotechnology. Both directors qualify as independent under New York Stock Exchange regulations. They will participate in the company's non-employee director compensation arrangements as outlined in the 2024 Proxy Statement. No material transactions involving the company and the new directors have been reported since the beginning of the last fiscal year.

Oct 22, 2025 16:15:48

International Flavors & Fragrances Announces New Accounting Officer

International Flavors & Fragrances Inc. appointed Marc Birenkrant as Controller & Chief Accounting Officer, effective August 10, 2025. Birenkrant has over 30 years of finance and accounting experience, having been with the company since 2008 in various leadership roles. He previously worked at The Wendy’s Company and began his career at Ernst & Young LLP.

Birenkrant replaces Beril Yildiz, who has served in the role since 2022 and will assist in the transition before departing the company on December 31, 2025. Yildiz's departure qualifies for the company’s executive severance policy.

Aug 07, 2025 16:31:06

International Flavors & Fragrances Announces $500M Share Buyback Plan

International Flavors & Fragrances (IFF) reported its financial results for the second quarter of 2025, revealing net sales of $2.76 billion, a 4% decrease from the previous year. However, on a currency-neutral basis, sales increased by 3%, attributed to growth in various segments, including Taste and Health & Biosciences. The company also reported a reduction in leverage to 2.5x and reaffirmed its full-year financial guidance, anticipating sales between $10.6 billion and $10.9 billion and adjusted operating EBITDA between $2 billion and $2.15 billion.

Additionally, IFF's Board of Directors authorized a new share repurchase program allowing for the buyback of up to $500 million in common stock, which will be funded through available cash and operational cash flows. The company is also divesting its soy crush, concentrates, and lecithin business, which generated approximately $240 million in revenue in 2024, as part of its strategy to enhance its portfolio and maximize shareholder value. The transaction is expected to close by the end of 2025.

Aug 05, 2025 16:26:13

New Board Appointments at International Flavors & Fragrances Announced

International Flavors & Fragrances Inc. has appointed Mr. Jesus Mantas and Mr. Paul Fribourg to its board of directors, effective July 29, 2025. Mr. Mantas will join the Audit Committee and Innovation Committee, while Mr. Fribourg will serve on the Transaction Committee. Both individuals bring significant experience from their respective backgrounds, with Mr. Mantas having held leadership roles at IBM Consulting and Mr. Fribourg as Chairman and CEO of Continental Grain Company.

The board has confirmed that both new directors qualify as independent under the New York Stock Exchange rules. There are no arrangements or transactions involving the company that would indicate a material interest from either director. They will participate in the non-employee director compensation arrangements as outlined in the company's 2024 Proxy Statement filed earlier in March 2025.

Jul 30, 2025 16:11:38

IFF Reports Q1 2025 Results with Impairment Impact

IFF announced its financial results for the first quarter of 2025, reporting net sales of $2.84 billion, a 2% decline compared to the previous year. The company experienced a significant loss before taxes of $994 million, largely due to a goodwill impairment of $1.15 billion in its Food Ingredients segment. However, adjusted operating EBITDA for the quarter was $578 million, reflecting a 9% increase year-over-year when adjusted for currency fluctuations. The company's segments, including Taste and Pharma Solutions, showed growth in currency neutral sales, with Taste segment sales rising by 7% on a comparable basis.

Despite the challenges posed by macroeconomic factors, IFF maintained its full-year guidance, anticipating sales between $10.6 billion and $10.9 billion and adjusted operating EBITDA ranging from $2 billion to $2.15 billion. The company noted that foreign exchange rates would negatively impact its sales and EBITDA growth projections. The early divestiture of its Pharma Solutions business is expected to have a significant effect on its financial outlook, with estimates indicating a 7% adverse impact on sales growth for 2025.

May 06, 2025 16:22:24